PaxMedica Share Holder Equity 2021-2024 | PXMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

PaxMedica share holder equity from 2021 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

PaxMedica share holder equity from 2021 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$142.2B
Bristol Myers Squibb (BMY)	$117.1B
Gilead Sciences (GILD)	$117.1B
Vertex Pharmaceuticals (VRTX)	$105.1B
CSL (CSLLY)	$85.9B
Regeneron Pharmaceuticals (REGN)	$78.5B
GSK (GSK)	$70.5B
Argenex SE (ARGX)	$38B
Alnylam Pharmaceuticals (ALNY)	$31.4B
BioNTech SE (BNTX)	$27.4B
Biogen (BIIB)	$21.7B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$17.7B
Moderna (MRNA)	$15.5B
Genmab (GMAB)	$13.5B
Incyte (INCY)	$13.5B
BioMarin Pharmaceutical (BMRN)	$12.7B
Insmed (INSM)	$12.6B
Sarepta Therapeutics (SRPT)	$11.6B
Bio-Techne Corp (TECH)	$11.6B
Exact Sciences (EXAS)	$10.8B
Vaxcyte (PCVX)	$10.7B
QIAGEN (QGEN)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$9.8B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$9B
Roivant Sciences (ROIV)	$8.7B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8.2B